Jagsonpal Pharmaceuticals Limited
JAGSNPHARM · ISIN: INE048B01035
Jagsonpal Pharmaceuticals Limited is a small cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE048B01035.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
CHART
Jagsonpal Pharmaceuticals Limited - growth of ₹100
Growth of ₹100 invested on 2026-05-08, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
-6.65%
3M
-3.84%
6M
+5.5%
1Y
+2.95%
3Y CAGR
-18.25%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Jagsonpal Pharmaceuticals Limited - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
Not available for this stock yet.
Corporate Actions
No corporate actions on record for this stock.
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-09-24 | BULK | 3,31,971 |
| 2026-09-24 | BULK | 4,23,870 |
| 2026-09-24 | BULK | 3,31,971 |
| 2026-09-24 | BULK | 4,23,870 |
Frequently asked questions
What is Jagsonpal Pharmaceuticals Limited's 1-year and 3-year return?
Jagsonpal Pharmaceuticals Limited's 1-year price return is +2.95%. Its 3-year CAGR (annualized return) is -18.25%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Jagsonpal Pharmaceuticals Limited's latest financial performance?
Jagsonpal Pharmaceuticals Limited's trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹316 Cr, with a TTM profit after tax of ₹45 Cr and an EBITDA margin of 5.29%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹6.78, with a 5-year EPS growth rate of -3.64% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Jagsonpal Pharmaceuticals Limited's quality score?
Jagsonpal Pharmaceuticals Limited has a Punji quality score of 54.5 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Jagsonpal Pharmaceuticals Limited's technical indicators show?
As of 2026-10-29, Jagsonpal Pharmaceuticals Limited's RSI (14-day) is 46.6 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in neutral territory. Its 50-day moving average is currently above its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Has Jagsonpal Pharmaceuticals Limited seen any recent bulk or block deals?
Yes, as of 2026-09-24 - the most recent recorded deal was a BULK on 2026-09-24 for 3,31,971 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
Stock data · Not financial advice · Past performance does not indicate future returns